Oxford Biomedica plc

OXB

GB00BDFBVT43

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 16:35:17 09/02/2026 GMT			5-day change	1st Jan Change
830.00 ^GBX	+2.60%		-0.12%	+34.52%

02-04	OXB Signs New Multi-Year Commercial Supply Agreement with Bristol Myers Squibb	CI
02-04	Oxford BioMedica expands cancer therapy deal with Bristol-Myers Squibb	AN

Oxford BioMedica signs multi-year supply agreement with Bristol Myers Squibb

Published on 02/04/2026 at 08:10 am GMT

Reuters

Latest news about Oxford Biomedica plc

02-04	OXB Signs New Multi-Year Commercial Supply Agreement with Bristol Myers Squibb	CI
02-04	Oxford BioMedica expands cancer therapy deal with Bristol-Myers Squibb	AN
02-04	Oxford Biomedica Enters Commercial Supply Deal for Lentiviral Vectors	MT
02-04	Oxford BioMedica signs multi-year supply agreement with Bristol Myers Squibb	RE
01-15	Rotation Tests Market Faith
01-15	Easing and Rotation
01-15	UK Stocks-Factors to watch on January 15	RE
01-15	PRESS DIGEST-Financial Times - January 15	RE
01-15	Oxford Biomedica Confirms Preliminary Merger Talks with EQT	MT
01-14	Oxford Biomedica confirms fresh EQT takeover approach	AN
01-14	Oxford BioMedica receives unsolicited approach from EQT	RE
01-14	UK's Oxford Biomedica confirms unsolicited bid from funds managed by EQT	RE
01-13	Eqt X Usd Scsp and Eqt X Eur Scsp, managed by Eqt Fund Management S.à R.L., proposed to acquire Oxford Biomedica plc.	CI
01-09	Berenberg raises M&S; BofA cuts Barratt Redrow	AN
01-06	London's FTSE 100 finishes at record high on healthcare gains	RE
01-06	Deutsche Bank Upgrades Oxford Biomedica to Buy, Boosts PT	MT
01-06	RBC raises Diageo; BofA cuts JD Sports Fashion	AN
12-08	JPMorgan cuts M&G, UBS cuts Trainline	AN
20/10/25	Oxford Biomedica plc Announces Stepping Down of Robert Ghenchev as Non-Executive Director, Effective October 20, 2025	CI
07/10/25	OXB Expands US Footprint with Acquisition of Commercial-Scale Viral Vector Facility in North Carolina	CI
07/10/25	Oxford BioMedica expands US footprint as buys North Carolina facility	AN
07/10/25	UK's Oxford Biomedica Buys Viral Vector Manufacturing Facility in US	MT
07/10/25	Oxford BioMedica announces acquisition of US viral vector facility	RE
06/10/25	Oxford Biomedica plc acquired Viral vector manufacturing facility in North Carolina from RTP Operating, LLC for $4.5 million.	CI
23/09/25	Oxford Biomedica plc, H1 2025 Earnings Call, Sep 23, 2025

Oxford Biomedica PLC is a contract development and manufacturing organization (CDMO) in cell and gene therapy. It provides viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. It offers several technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the Tetravecta system), dual plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines. It has bioprocessing and manufacturing facilities across Oxfordshire, United Kingdom, Lyon and Strasbourg, France and near Boston, MA, United Sates. Its Platform segment is involved in bioprocessing and process development activities undertaken for third parties. Its Viral Vector includes LentiVector platform, inAAVate platform, and Other Viral Vectors. Its LentiVector platform technology is an advanced lentiviral vector-based gene delivery system.

Employees

900

Sector

Biotechnology & Medical Research

More about the company